Stapleless vs Stapled Gastric Bypass vs Hypocaloric Diet: a Three-Arm Randomized Controlled Trial of Body Mass Evolution with Secondary Outcomes for Telomere Length and Metabolic Syndrome Changes.
Bariatric surgery
Metabolic syndrome
RCT
Randomized controlled trial
Telomere
Journal
Obesity surgery
ISSN: 1708-0428
Titre abrégé: Obes Surg
Pays: United States
ID NLM: 9106714
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
31
10
2020
accepted:
27
04
2021
revised:
22
04
2021
pubmed:
9
5
2021
medline:
29
6
2021
entrez:
8
5
2021
Statut:
ppublish
Résumé
Obesity and metabolic syndrome (MetS) reduce life expectancy and are challenging to resolve. This randomized controlled trial (RCT) of patients with obesity and MetS undergoing surgical vs nonsurgical treatment compared changes in BMI, and secondarily, telomere length (as a biomarker of life expectancy) and changes in MetS components (insulin resistance, dyslipidemia, hypertension). Study design was a single-center, prospective, three-arm RCT. Group 1 patients underwent novel unstapled laparoscopic one anastomosis gastric bypass with an obstructive stapleless pouch and anastomosis (LOAGB-OSPAN); Group 2, stapled laparoscopic mini-gastric bypass-one anastomosis gastric bypass (LMGB-OAGB); and Group 3, nonsurgical weight loss therapy via a hypocaloric diet with energy restriction (HDER). The primary outcome measure was change in BMI; secondary outcome measures included change in leukocyte telomere length and other MetS components. Of 96 participants screened, 60 were randomly allocated to 3 groups: LOAGB-OSPAN group (n = 20), LMGB-OAGB group (n = 20), and HDER group (n = 20). At post-treatment month 12, respective BMI changes: BMI -12.13 (-8.34, -15.93); -16.04 (-11.7, 20.37); -2,76 (-3.84, -9.36) (p < 0.01). The two surgical groups experienced significant change in telomere length: LOAGB-OSPAN 2.02 (1.61, 2.41), p = 0.001; LMGB-OAGB 2.07 (1.72, 2.43), p = 0.001; and HDER 0.28 (0.22, 0.78), p = 0.26. The surgical groups were also more effective in treating MetS components. There were no deaths. Adverse events: LOAGB-OSPAN (n = 2) (Clavien-Dindo grade II); LMGB-OAGB (n = 8) (grade I (n = 6) and grade II (n = 2). Compared with hypocaloric diet therapy, both bariatric procedures resulted in greater BMI loss, and secondarily, a significant increase in telomere length, and greater MetS resolution. ClinicalTrials.gov , NCT03667469, registered on 11 September 2018.
Sections du résumé
BACKGROUND
Obesity and metabolic syndrome (MetS) reduce life expectancy and are challenging to resolve. This randomized controlled trial (RCT) of patients with obesity and MetS undergoing surgical vs nonsurgical treatment compared changes in BMI, and secondarily, telomere length (as a biomarker of life expectancy) and changes in MetS components (insulin resistance, dyslipidemia, hypertension).
METHODS
Study design was a single-center, prospective, three-arm RCT. Group 1 patients underwent novel unstapled laparoscopic one anastomosis gastric bypass with an obstructive stapleless pouch and anastomosis (LOAGB-OSPAN); Group 2, stapled laparoscopic mini-gastric bypass-one anastomosis gastric bypass (LMGB-OAGB); and Group 3, nonsurgical weight loss therapy via a hypocaloric diet with energy restriction (HDER). The primary outcome measure was change in BMI; secondary outcome measures included change in leukocyte telomere length and other MetS components.
RESULTS
Of 96 participants screened, 60 were randomly allocated to 3 groups: LOAGB-OSPAN group (n = 20), LMGB-OAGB group (n = 20), and HDER group (n = 20). At post-treatment month 12, respective BMI changes: BMI -12.13 (-8.34, -15.93); -16.04 (-11.7, 20.37); -2,76 (-3.84, -9.36) (p < 0.01). The two surgical groups experienced significant change in telomere length: LOAGB-OSPAN 2.02 (1.61, 2.41), p = 0.001; LMGB-OAGB 2.07 (1.72, 2.43), p = 0.001; and HDER 0.28 (0.22, 0.78), p = 0.26. The surgical groups were also more effective in treating MetS components. There were no deaths. Adverse events: LOAGB-OSPAN (n = 2) (Clavien-Dindo grade II); LMGB-OAGB (n = 8) (grade I (n = 6) and grade II (n = 2).
CONCLUSIONS
Compared with hypocaloric diet therapy, both bariatric procedures resulted in greater BMI loss, and secondarily, a significant increase in telomere length, and greater MetS resolution.
TRIAL REGISTRATION
ClinicalTrials.gov , NCT03667469, registered on 11 September 2018.
Identifiants
pubmed: 33963974
doi: 10.1007/s11695-021-05454-2
pii: 10.1007/s11695-021-05454-2
doi:
Banques de données
ClinicalTrials.gov
['NCT03667469']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3165-3176Références
Saklayan MG. The global epidemic of the metabolic syndrome. Curr Hypertens Rep. 2018;20(2):12. https://doi.org/10.1007/s11906-018-0812-z .
doi: 10.1007/s11906-018-0812-z
Rubino F, Nathan DM, Eckel RH, et al. Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. Diabetes Care. 2016;39:861–77.
doi: 10.2337/dc16-0236
Wadden TA, Foster GD, Letizia KA. One-year behavioral treatment of obesity: Comparison of moderate and severe caloric restriction and the effects of weight maintenance therapy. J Consult Clin Psychol. 1994;62(1):165–71.
doi: 10.1037/0022-006X.62.1.165
Park HS, Song YM, Cho SI. Obesity has a greater impact on cardiovascular mortality in younger men than in older men among non-smoking Koreans. Int J Epidemiol. 2006;35:181–7.
doi: 10.1093/ije/dyi213
Gloy VL, Briel M, Bhatt DL, et al. Bariatric surgery versus nonsurgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials. BMJ. 2013;347:f5934.
doi: 10.1136/bmj.f5934
Tzanetakou IP, Katsilambros NL, Benetos A, et al. Is obesity linked to aging?: Adipose tissue and the role of telomeres. Aging Res Rev. 2012;11(2):220–9. https://doi.org/10.1016/j.arr.2011.12.003 .
doi: 10.1016/j.arr.2011.12.003
Paul L. Diet, nutrition and telomere length. J Nutr Biochem. 2011;22(10):895–901. https://doi.org/10.1016/j.jnutbio.2010.12.001 .
doi: 10.1016/j.jnutbio.2010.12.001
pubmed: 21429730
Fasching CL. Telomere length measurement as a clinical biomarker of aging and disease. Crit Rev Clin Lab Sci. 2018;55(7):443–65. https://doi.org/10.1080/10408363.2018.1504274 .
doi: 10.1080/10408363.2018.1504274
pubmed: 30265166
Valdes AM, Andrew T, Gardner JP, et al. Obesity, cigarette smoking, and telomere length in women. Lancet. 2005;366(9486):662–4. https://doi.org/10.1016/S0140-6736(05)66630-5 .
doi: 10.1016/S0140-6736(05)66630-5
pubmed: 16112303
Mundstock E, Sarria EE, Zatti H, et al. Effect of obesity on telomere length: systematic review and meta-analysis. Obesity. 2015;23:2165–74.
doi: 10.1002/oby.21183
Njajou OT, Cawthon RM, Blackburn EH, et al. Shorter telomeres are associated with obesity and weight gain in the elderly. Int J Obes. 2012;36:1176–9.
doi: 10.1038/ijo.2011.196
O’Callaghan NJ, Clifton PM, Noakes M, et al. Weight loss in obese men is associated with increased telomere length and decreased abasic sites in rectal mucosa. Rejuvenation Res. 2009;12:169–76.
doi: 10.1089/rej.2008.0819
Laimer M, Melmer A, Lamina C, et al. Telomere length increase after weight loss induced by bariatric surgery: results from a 10 year prospective study. Int J Obes. 2016;40(5):773–8. https://doi.org/10.1038/ijo.2015.238 .
doi: 10.1038/ijo.2015.238
Morton JM, Garg T, Leva N. Association of laparoscopic gastric bypass surgery with telomere length in patients with obesity. JAMA Surg. 2019;154(3):266–8. https://doi.org/10.1001/jamasurg.2018.4830 .
doi: 10.1001/jamasurg.2018.4830
pubmed: 30566188
Formichi C, Cantara S, Ciuoli C, et al. Weight loss associated with bariatric surgery does not restore short telomere length of severe obese patients after 1 year. Obes Surg. 2014;24(12):2089–93. https://doi.org/10.1007/s11695-014-1300-4 .
doi: 10.1007/s11695-014-1300-4
pubmed: 24913239
Ospanov O, Yeleuov G, Kadyrova I, et al. The life expectancy of patients with metabolic syndrome after weight loss: study protocol for a randomized clinical trial (LIFEXPE-RT). Trials. 2019;20:202. https://doi.org/10.1186/s13063-019-3304-9 .
doi: 10.1186/s13063-019-3304-9
pubmed: 30961631
pmcid: 6454761
Ospanov OB. Surgical technique of laparoscopic mini-gastric bypass with obstructive stapleless pouch creation: a case series. Int J Surg. 2019;67:70–5. https://doi.org/10.1016/j.ijsu.2019.05.011 .
doi: 10.1016/j.ijsu.2019.05.011
pubmed: 31158507
Ospanov O. The surgical technique of stapleless laparoscopic one-anastomosis gastric bypass with an uncut pouch creation: a randomized clinical trial. Bariatric Surg Pract Patient Care. Published online, Mary Ann Liebert, Inc. 2020; https://doi.org/10.1089/bari.2020.0068 .
Bhandari M, Fobi MAL, Buchwald JN, et al. Standardization of bariatric metabolic procedures: World Consensus Meeting Statement. Obes Surg. 2019;29(Suppl 4):309–45. https://doi.org/10.1007/s11695-019-04032-x .
doi: 10.1007/s11695-019-04032-x
pubmed: 31297742
Brethauer SA, Kim J, el Chaar M, et al. Standardized outcomes reporting in metabolic and bariatric surgery. Surg Obes Relat Dis. 2015;11(3):489–506. https://doi.org/10.1016/j.soard.2015.02.003 .
doi: 10.1016/j.soard.2015.02.003
pubmed: 26093765
Cawthon RM. Telomere measurement by quantitative PCR. Nucleic Acids Res. 2002;30(10):e47. https://doi.org/10.1093/nar/30.10.e47 .
doi: 10.1093/nar/30.10.e47
pubmed: 12000852
pmcid: 115301
Kirchner H, Shaheen F, Kalscheuer H, et al. The telomeric complex and metabolic disease. Genes. 2017;8:176. https://doi.org/10.3390/genes8070176 .
doi: 10.3390/genes8070176
pmcid: 5541309
Salminen P, Helmiö M, Ovaska J, et al. Effect of laparoscopic sleeve gastrectomy vs laparoscopic Roux-en-Y gastric bypass on weight loss at 5 years among patients with morbid obesity: The SLEEVEPASS randomized clinical trial. JAMA. 2018;319(3):241–54. https://doi.org/10.1001/jama.2017.20313 .
doi: 10.1001/jama.2017.20313
pubmed: 29340676
pmcid: 5833550
Wittes J. Sample size calculations for randomized controlled trials. Epidemiol Rev. 2002;24(1):39–53. https://doi.org/10.1093/epirev/24.1.39 .
doi: 10.1093/epirev/24.1.39
pubmed: 12119854
Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien–Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250:187–96.
doi: 10.1097/SLA.0b013e3181b13ca2
Ospanov O. Thanks IFSO for the support that allowed inclusion of the specialization “Bariatric and Metabolic Surgery” in the healthcare system of Kazakhstan. Obes Surg. 2021; https://doi.org/10.1007/s11695-021-05232-0 .
Cummings DE, Cohen RV. Beyond BMI: the need for new guidelines governing the use of bariatric and metabolic surgery. Lancet Diabetes Endocrinol. 2014;2(2):175–81. https://doi.org/10.1016/S2213-8587(13)70198-0 .
doi: 10.1016/S2213-8587(13)70198-0
pubmed: 24622721
pmcid: 4160116
Jongbloed F, Meijers RWJ, Ijzermans JNM, et al. Effects of bariatric surgery on telomere length and T-cell aging. Int J Obes. 2019;43:2189–99. https://doi.org/10.1038/s41366-019-0351-y .
doi: 10.1038/s41366-019-0351-y
Shantavasinkul PC, Muehlbauer MJ, Bain JR, et al. Improvement in insulin resistance after gastric bypass surgery is correlated with a decline in plasma 2-hydroxybutyric acid. Surg Obes Relat Dis. 2018;14(8):1126–32. https://doi.org/10.1016/j.soard.2018.03.033 .
doi: 10.1016/j.soard.2018.03.033
pubmed: 29805089
pmcid: 6153057
Ribaric G, Buchwald JN, McGlennon TW. Diabetes and weight in comparative studies of bariatric surgery vs conventional medical therapy: a systematic review and meta-analysis. Obes Surg. 2014;24:437–55.
doi: 10.1007/s11695-013-1160-3
Schauer PR, Ikramuddin S, Gourash W, et al. Outcomes after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Ann Surg. 2000;232:515–29.
doi: 10.1097/00000658-200010000-00007
Cummings DE, Arterburn DE, Westbrook EO, et al. Gastric bypass surgery vs intensive lifestyle and medical intervention for type 2 diabetes: The CROSSROADS randomised controlled trial. Diabetologia. 2016;59:945–53.
doi: 10.1007/s00125-016-3903-x
Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med. 2012;366:1577–85.
doi: 10.1056/NEJMoa1200111
Ikramuddin S, Korner J, Lee WJ, et al. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial. JAMA. 2013;309:2240–9.
doi: 10.1001/jama.2013.5835
Batsis JA, Sarr MG, Collazo-Clavell ML, et al. Cardiovascular risk after bariatric surgery for obesity. Am J Cardiol. 2008;102(7):930–7.
doi: 10.1016/j.amjcard.2008.05.040
Schiavon CA, Bersch-Ferreira AC, Santucci EV, et al. Effects of bariatric surgery in obese patients with hypertension: the GATEWAY randomized trial (Gastric Bypass to Treat Obese Patients With Steady Hypertension). Circulation. 2018;137(11):1132–42.
doi: 10.1161/CIRCULATIONAHA.117.032130
Liang Z, Wu Q, Chen B, et al. Effect of laparoscopic Roux-en-Y gastric bypass surgery on type 2 diabetes mellitus with hypertension: a randomized controlled trial. Diabetes Res Clin Pract. 2013;101:50–6.
doi: 10.1016/j.diabres.2013.04.005
Gero D, Raptis DA, Vleeschouwers W, et al. Defining global benchmarks in bariatric surgery: a retrospective multicenter analysis of minimally invasive Roux-en-Y gastric bypass and sleeve gastrectomy. Ann Surg. 2019;270(5):859–67. https://doi.org/10.1097/SLA.0000000000003512 .
doi: 10.1097/SLA.0000000000003512
pubmed: 31592894